Healthcare company Penumbra has announced the initial INSIGHT Registry data regarding the use of RED reperfusion catheters for broad stroke care.

The data demonstrated that the RED reperfusion catheters were successful in removing all clot types.

The findings were presented at the 2022 World Federation of Interventional and Therapeutic Neuroradiology (WFITN) in Kyoto, Japan.

The initial data was collected from 161 patients with AIS in a multi-centre post-market assessment called the INSIGHT Registry.

The data evaluating the catheters revealed that 68.9% had effective first-pass revascularisation (mTICI2b-3), and 97.0% had successful revascularisation after final angiography through site-reported findings.

The company added that final mTICI≥2b-3 scores were reported in 98.1% of patients with firm-red clots and in 100% of patients with other clot types.

Penumbra interventional president Sandra Lesenfants: “The initial data from our INSIGHT Registry is very promising. With such a high first pass rate, Penumbra’s RED catheters can restore blood flow much quicker, which we know can lead to improved outcomes for patients.”

Sub-analyses of the COMPLETE study demonstrated that the Penumbra System is effective for acute ischemic stroke (AIS) patients with tandem lesions as well as for late window patients.

COMPLETE study national principal investigator Osama Zaidat said: “Mechanical aspiration thrombectomy is becoming an increasingly important option for physicians treating acute ischemic stroke, especially patients with more complicated cases.

“Oftentimes, patients that presented late or have tandem lesions (15% of MT cases) are difficult to treat.

“However, the data showed the Penumbra System delivered good functional outcomes and low 90-day mortality rates for these patients, which compared favourably to other options.”